These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10753128)

  • 1. Vaccines and medicines for the world's poorest. Public-private partnerships seem to be essential.
    Smith R
    BMJ; 2000 Apr; 320(7240):952-3. PubMed ID: 10753128
    [No Abstract]   [Full Text] [Related]  

  • 2. Public-private partnerships: an overview.
    Widdus R
    Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S1-8. PubMed ID: 16085172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
    Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D
    PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines and medicines for the world's poorest. Quality of vaccines and medicines must be monitored.
    Arya SC
    BMJ; 2000 Sep; 321(7264):834. PubMed ID: 11009543
    [No Abstract]   [Full Text] [Related]  

  • 5. Public-private partnerships for health: their main targets, their diversity, and their future directions.
    Widdus R
    Bull World Health Organ; 2001; 79(8):713-20. PubMed ID: 11545327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. World's poorest countries can improve access to medicines through local production, says United Nations.
    Zarocostas J
    BMJ; 2011 May; 342():d3101. PubMed ID: 21593099
    [No Abstract]   [Full Text] [Related]  

  • 7. Public-private partnerships: new ways to discover, develop and deliver drugs for tropical diseases.
    Hentschel CC
    Southeast Asian J Trop Med Public Health; 2004; 35 Suppl 2():1-4. PubMed ID: 15906625
    [No Abstract]   [Full Text] [Related]  

  • 8. Availability and affordability of priority life-saving medicines for under-five children in health facilities of Tigray region, northern Ethiopia.
    Abrha S; Tadesse E; Atey TM; Molla F; Melkam W; Masresha B; Gashaw S; Wondimu A
    BMC Pregnancy Childbirth; 2018 Nov; 18(1):464. PubMed ID: 30497441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases.
    Ewen M; Zweekhorst M; Regeer B; Laing R
    PLoS One; 2017; 12(2):e0171284. PubMed ID: 28170413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From the World Health Organization. State of the World's Vaccines and Immunizations.
    JAMA; 2002 Nov; 288(20):2532. PubMed ID: 12444848
    [No Abstract]   [Full Text] [Related]  

  • 11. A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more.
    Hotez P
    Health Aff (Millwood); 2011 Jun; 30(6):1080-7. PubMed ID: 21653960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicines and vaccines for the world's poorest: is there any prospect for public-private cooperation?
    Scheffler RM; Pathania V
    Global Health; 2005 Jul; 1():10. PubMed ID: 16042765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines, global health and social equity.
    Levine MM; Robins-Browne R
    Immunol Cell Biol; 2009; 87(4):274-8. PubMed ID: 19308074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public-private partnerships and global health equity: prospects and challlenges.
    Asante AD; Zwi AB
    Indian J Med Ethics; 2007; 4(4):176-80. PubMed ID: 18630239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The introduction of new vaccines into developing countries. IV: Global Access Strategies.
    Mahoney RT; Krattiger A; Clemens JD; Curtiss R
    Vaccine; 2007 May; 25(20):4003-11. PubMed ID: 17363119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linking research to global health equity: the contribution of product development partnerships to access to medicines and research capacity building.
    Pratt B; Loff B
    Am J Public Health; 2013 Nov; 103(11):1968-78. PubMed ID: 24028246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of emerging manufacturers in access to innovative vaccines of public health importance.
    Milstien JB; Kaddar M
    Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unlocking the potential of the world's children through sustainable fortification and public-private partnership. Proceedings of a colloquium. October 10-11, 2002. Cincinnati, Ohio, USA.
    Food Nutr Bull; 2003 Dec; 24(4 Suppl):S65-162. PubMed ID: 17061374
    [No Abstract]   [Full Text] [Related]  

  • 19. [Quality of medicines in least developed countries].
    Videau JY
    Med Trop (Mars); 2006 Dec; 66(6):533-7. PubMed ID: 17286015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulating pharmaceutical research and development for neglected diseases.
    Mrazek MF; Mossialos E
    Health Policy; 2003 Apr; 64(1):75-88. PubMed ID: 12644330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.